Merck & Co., Inc. is 252.1x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($293.16 B vs $1.16 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | XERS | MRK |
|---|---|---|
| Market cap | $1.16 B | $293.16 B |
| US-listed rank | #2530 | #44 |
| Revenue (latest FY) | $291.85M | $65.01B |
| Net income (latest FY) | $554.00K | $18.25B |
| Net margin | 0.2% | 28.1% |
| P/E (trailing FY) | 2098.8 | 16.1 |
| SEC filings | 290 | 996 |
Merck & Co., Inc. is 252.1x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($293.16 B vs $1.16 B).
In their latest fiscal years, Xeris Biopharma Holdings, Inc. reported $291.85M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Xeris Biopharma Holdings, Inc. and Merck & Co., Inc., or browse the full rankings.